is on a mission to change the future for millions of cancer patients. We are developing novel therapies that target the most aggressive cancer cells through a first-in-class mechanism of action, and demonstrate a high level of selectivity for the reprogrammed cancer mitochondria.
Penrose has developed a novel Mitochondrial Modifying Agent (MMA) therapeutic platform designed to generate therapies that kill some of the most difficult to treat cancers. Highly selective oral small molecules target cancer mitochondria in a cooperative fashion, leading to necrotic cell death.
President and Chief Executive Officer
Dr. David Sherris brings over three decades of experience to the Penrose table in translational medicine involving basic research, pharmaceutics and diagnostics.
Chief Medical Officer
Dr. Gill is a practicing cardio-oncologist with extensive experience in healthcare management and is a founding member of Penrose TherapeuTx.
Chief Development Officer
Dr. Desai is a hematologist and medical oncologist with three decades of clinical oncology. He is a leader in oncology clinical drug development across all classes of medication and phases of development.
Director of Chemistry, Manufacturing, and Controls
Chief Financial Officer & Chief Operating Officer
Mr. Schutt has over a decade of experience in balance sheet optimization, corporate finance, investment banking, and business development with publicly traded and privately held financial institutions ranging from $250 million to $25 billion in assets. He is also a founding member of Penrose TherapeuTx.
November 15, 2021
May 28, 2021
May 11, 2021